Drug Images
Intermittent Therapy -80 mg/kg administered orally as a single dose
Locally advanced squamous cell carcinomas of the
Patients who had been receiving a stable or decreasing dose of hydroxyurea, interferon alfa, or ruxolitinib for at least 8 weeks before the first
1 Dosing Information - Hydroxyurea is used alone or in conjunction with other antitumor agents or
Hydroxyurea capsules are indicated for the treatment of: Resistant chronic myeloid leukemia
On December 21, 2017, the Food and Drug Administration granted regular approval to hydroxyurea (Siklos, Addmedica) to reduce the frequency of painful crises and the need for blood transfusions in In animal reproduction studies, hydroxyurea administration to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0
The Food and Drug Administration (FDA) approved it for treating adults with sickle cell disease in 1998
2 times the maximum recommended human oral daily dose on a mg/m 2 basis) thrice weekly for 6 months to female rats increased the incidence of mammary tumors in rats surviving to 18 months compared to control
8 times and 0
3 times, respectively, the maximum recommended human daily dose on a mg/m 2 basis (see Data)
loss of appetite
Hydroxyurea concentrations were determined with a colorimetric technique as described previously 13
Distribution In animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0
8 times and 0
Patients fasted 8 hours before and 4 hours after the administration of oral hydroxyurea
Hydroxyurea capsules may cause macrocytosis, which is self-limiting, and is often seen early in the course of treatment
When administered at once-daily oral doses that lead to mild marrow suppression, hydroxyurea leads to substantial and sustained fetal hemoglobin induction, which effectively inhibits erythrocyte sickling
1) The dose may be increased by 5 mg/kg/day every 12 weeks until a maximum tolerated dose or 35 mg/kg/day is reached if blood counts are in an acceptable range
In 20 patients who continued therapy for ≥ 2 months, there was statistically significant reduction of bone pain, abdominal pain, diarrhea, bloating Patients should swallow hydroxyurea capsules whole and not to open, since hydroxyurea is a cytotoxic drug